CRNX vs XERS
CRNX: A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases. XERS: A commercial-stage biopharma company with three FDA-approved therapies for rare endocrine and neurological diseases and a proprietary injectable drug formulation platform for rare diseases.
Side-by-side fundamentals
| Metric | CRNX | XERS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $83.72 | $8.38 | |
| Market cap as of 2026-07-23 | $8.9B | $1.5B | |
| P/E as of 2026-07-23 | n/a | 123.28 | |
| PEG as of 2026-07-23 | -0.47 | 2.29 | CRNX lower |
| Net margin as of 2026-07-23 | -2747.2% | +3.8% | XERS higher |
| Gross margin as of 2026-07-23 | +86.0% | +85.9% | CRNX higher |
| Operating margin as of 2026-07-23 | -3020.3% | +11.4% | XERS higher |
| ROE as of 2026-07-23 | -44.0% | +99.7% | XERS higher |
| ROA as of 2026-07-23 | -39.6% | +3.2% | XERS higher |
| Debt / equity as of 2026-07-23 | 0.00 | 17.00 | CRNX lower |
| Revenue growth (YoY) as of 2026-07-23 | +2277.5% | +41.5% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +38.3% | |
| Beta as of 2026-07-23 | 0.11 | 0.75 | |
| 1-year return as of 2026-07-22 close | +171.1% | +63.7% | CRNX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.